DNAe Previews its Semiconductor Genomic Analysis Test to Address the Challenge of Sepsis

LiDia™ Bloodstream Infection (BSI) Test showcased at an Imperial College/Royal Institution *Technology vs Infectious Diseases* Summit, London

London, UK and Carlsbad, CA, USA – 26 September 2017 – DNAe, the inventor of semiconductor based genomic analysis technologies, and the developer of a new, game-changing test for diagnosis of bloodstream infections that can lead to sepsis, previews its LiDia™ bloodstream infection (BSI) test today at the '*Technology vs Infectious Diseases*' Summit held at the Royal Institution in London.

Sepsis kills around 6 million people worldwide every year. In the UK alone the number reaches 44,000 which is more than bowel, breast, and prostate cancer combined. Treatment in the early stages is crucial so there is an urgent need for early diagnosis through rapid tests.

Organised by Imperial College and the Royal Institution (Ri), the Summit highlights the best of British technology in the fight against the global threat of infectious diseases. An afternoon of presentations showcasing how cutting-edge UK research and pioneering technological solutions are contributing to tackling infectious diseases and antimicrobial resistance worldwide. An evening event featuring a keynote address by Prof David Heymann, Professor of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine; Head of the Centre on Global Health Security at Chatham House, London; and former Chairman of Public Health England, UK.

DNAe's Chief Scientific Officer, Mr David Davidson, presented during the Summit programme on *'Infectious Disease Diagnostics using Third Generation Sequencing on a Microchip'*.

Professor Chris Toumazou, Regius Professor of Engineering at Imperial College, Trustee of the Royal Institution, and Founder and Executive Chairman of DNAe, commented: "It is an honour to be pioneering ground-breaking third generation semiconductor DNA analysis technology. We are especially pleased to preview our breakthrough genomic analysis test for diagnosis of bloodstream infections, at the historic Ri building – where Michael Faraday undertook his experiments around semiconductor properties, and where the father of antibiotics, Alexander Fleming, presented to the Ri in 1953. Innovation is a long road, so it's exciting to be close to launch with a world-leading technology that has the potential to transform the clinical management of sepsis."

DNAe's LiDia™ BSI is a rapid test for serious bloodstream infections leading to sepsis. At launch, the LiDia™ BSI Test is designed to enable the precise identification of the infecting organism directly from an unprocessed blood sample within 3 hours, arming clinicians with the information that they need to provide swift treatment with the right antimicrobial drugs. Quick and appropriate treatment is the key to achieving the best prognosis for patients. Currently accurate diagnosis can take several days.

"DNAe is currently testing our end-to-end LiDia™ BSI test using clinical samples and will be presenting results at the Association for Molecular Pathology meeting (AMP) in Salt Lake City, USA in November. The Company plans to apply for CE mark approval in 2018, to enable us to bring this urgently needed test to market in Europe" said DNAe's Group Chief Executive Officer Dr Steve Allen.

Underlining the world-leading nature of DNAe's innovation and the game-changing nature of its semiconductor DNA genomic analysis technologies, the US BARDA has awarded the company up to $51.9m to develop its sequencing platform for rapid diagnosis in two key applications; antimicrobial resistant infections and influenza. The Company is also exploring applications in diagnosis of cancer from liquid biopsies.

—Ends—

Professor Chris Toumazou, Regius Professor of Engineering at Imperial College, Trustee of the Royal Institution, and Founder and Executive Chairman of DNAe, with a semiconductor DNA sequencing chip. Copyright DNA Electronics.

About DNAe – www.dnae.com
DNAe is commercializing its pioneering semiconductor DNA sequencing technology for healthcare applications where rapid near-patient live diagnostics is needed to provide actionable information to clinicians, saving lives by enabling the right treatment at the right time.

In January 2015 DNAe acquired nanoMR, Inc. (now DNA Electronics Inc.), a developer of a novel system for rapid isolation of rare cells in the bloodstream. DNAe is developing LiDia™, its sample-to-result genomic analysis platform, combining DNA Electronics Inc.'s Pathogen Capture System with its own portfolio of semiconductor-based genomic technologies, trademarked Genalysis®. The LiDia™ range of tests will enable DNA analysis directly on a microchip, providing rapid and accurate results from a user-friendly system.

DNAe's initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. LiDia™ launches with the LiDia™ Bloodstream Infection (BSI) test, a groundbreaking rapid direct-from-specimen test for bloodstream infections that lead to sepsis. Built into a compact

device for use at the point of need, the system will diagnose accurately and rapidly what infection a patient has, providing the clinician with actionable information to help select the appropriate antibiotics to treat the disease.

In October 2016, the Biomedical Advanced Research and Development Authority (BARDA) a division of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) awarded DNAe a contract worth up to $51.9 million to develop Genalysis® for rapid diagnosis in two key applications; antimicrobial resistant infections and influenza.

A private company, with bases in London, UK and Carlsbad, CA, USA, DNAe has strong financial backing from its investors, including major shareholder Genting Berhad, a Malaysian-based global investor with a growing portfolio of cutting–edge life sciences companies.

Contact Details

DNAe
Dr Steve Allen, Chief Executive Officer, DNAe Group — Tel: +44 (0)20 7036 2100

Instinctif Partners (media relations) — Tel: +44 (0)20 7457 2020
Sue Charles / Ashley Tapp / Alex Bannister / Deborah Bell — Email: DNAe@instinctif.com